Veracyte Study Shows Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer

PUBT · 1d ago
Veracyte Study Shows Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer
  • Veracyte will present six genomic test studies at the ESMO Congress in Madrid, October 23-27, 2026.
  • Decipher Prostate findings will provide first evidence predicting benefit from adding abiraterone to androgen deprivation therapy in clinically very high-risk, nonmetastatic disease.
  • An October 25 presentation will examine the economics of Prosigna-guided chemotherapy decisions using two-year results from the Phase III OPTIMA breast cancer trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9848165) on October 19, 2026, and is solely responsible for the information contained therein.